(Q42612663)

English

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study

scientific article published on 11 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study (English)

1 reference

Europe PubMed Central

3 November 2017

adult attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

serotonin–norepinephrine reuptake inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Adel Gabriel

1

1 reference

Europe PubMed Central

3 November 2017

Claudio Violato

2

1 reference

Europe PubMed Central

3 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 August 2011

1 reference

Europe PubMed Central

3 November 2017

ADHD - Attention Deficit and Hyperactivity Disorders

1 reference

Europe PubMed Central

3 November 2017

3

1 reference

Europe PubMed Central

3 November 2017

319-326

1 reference

Europe PubMed Central

3 November 2017

4

1 reference

Europe PubMed Central

3 November 2017

https://scigraph.springernature.com/pub.10.1007/s12402-011-0063-1

0 references

Combination pharmacotherapy for adult ADHD.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Validity of pilot Adult ADHD Self- Report Scale (ASRS) to Rate Adult ADHD symptoms.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Functional outcomes in the treatment of adults with ADHD.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Treatment of attention-deficit/hyperactivity disorder: overview of the evidence

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

The mixed amphetamine salt extended release (Adderall XR, Max-XR) as an adjunctive to SSRIS or SNRIS in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety: an open-label study

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Rethinking the duration requirement for generalized anxiety disorder: evidence from the National Comorbidity Survey Replication.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL).

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

A randomized controlled trial of atomoxetine in generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Atomoxetine and Adult Attention-Deficit/Hyperactivity Disorder

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Remission versus response as the goal of therapy in ADHD: a new standard for the field?

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Escitalopram in the long-term treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Cardiovascular effects of atomoxetine in children, adolescents, and adults

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD.

1 reference

https://api.crossref.org/works/10.1007%2FS12402-011-0063-1

21 January 2018

Identifiers

10.1007/S12402-011-0063-1

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42612663&oldid=1962834418"